Compare Citius Pharmaceuticals Inc (CTXR) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Endeavour Silver Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Endeavour Silver Corp trades at $8.04 (market cap $2.39B). The key difference: Endeavour Silver Corp is far larger — about 163.3× Citius Pharmaceuticals Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EXK | |
|---|---|---|
Market Cap | $14.64M | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $14.12 |
52-Week Low | $0.53 | $4.96 |
Enterprise Value | $10.86M | $2.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
EXK trades at $7.84, down 2.97% on the day, amid a bearish technical signal. The company reported strong Q1 2026 results with earnings of $0.21 per share beating estimates, driven by record production. However, full-year 2025 financials show a net loss of $119.10 million. Analyst sentiment is largely positive with 11 buy ratings, but the stock faces headwinds from negative profitability metrics and high valuation multiples.
The outlook is mixed; operational improvements and silver price trends offer upside, but persistent losses and bearish technicals pose risks. Investors should weigh the company's growth potential against its current financial health and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
